Biosynthema
Advanced Accelerator Applications (AAA), a Novartis Company, is a pioneer in nuclear medicine and is dedicated to transforming patients' lives through innovative radioligand therapies and precision imaging radioligands for oncology. With over 15 years of experience, AAA has developed a portfolio of PET and SPECT nuclear medicine imaging products for various indications in oncology, neurology, cardiology, and infectious inflammatory diseases.
AAA's mission is to develop targeted radioligand therapies that can be widely used in different tumor types, and their expertise is built on a strong legacy in nuclear medicine. They are committed to conducting clinical trials to discover new and improved ways to diagnose and treat diseases, and their global team of 1,000 associates operates in 12 countries, making AAA one of the four platforms of the Novartis Bold4Cure strategy.
Generated from the website

